Cochlear reaffirms $330–350M profit guidance

Hearing implant maker Cochlear (ASX:COH) reaffirmed its FY27 underlying net profit forecast of $330–$350 million and low single-digit constant currency revenue growth.

The company noted that trading between July and October matched internal expectations, keeping the assumptions from its August full-year results intact.

Cochlear stated that implant volumes in developed markets grew at a mid-single-digit rate during that four-month period, while North American president Lisa Aubert prepares to depart later this year after 32 years.

The company said its upcoming Capital Markets Day presentation at Macquarie University will outline adult implant growth opportunities, operational efficiency investments, and research linking hearing treatment to cognitive health and fall prevention.

Following the announcement, the Cochlear share price was up at $152.98.

Cochlear designs, manufactures, and supplies implantable hearing solutions globally, focusing on expanding adult adoption alongside its established paediatric market.

Over the past year, the company rolled out its Nucleus Nexa system across developed markets, launched the Osia 3 sound processor, reported FY26 underlying net profit of $322 million, and saw its share price fall roughly 40% year-to-date.